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bstract
With the development of minimally invasive surgical techniques, there is a growing interest in the research and development of injectable 
iomaterials especially for orthopedic applications. In a view to enhance the overall surgery benefits for the patient, the BIOSINJECT project aims 
t preparing a new generation of mineral-organic composites for bone regeneration exhibiting bioactivity, therapeutic activity and easiness of use 
o broaden the application domains of the actual bone mineral cements and propose an alternative strategy with regard to their poor resorbability, 
njectability difficulties and risk of infection. First, a physical-chemical study demonstrated the feasibility of self-setting injectable composites 
ssociating calcium carbonate-calcium phosphate cement and polysaccharides (tailor-made or commercial polymer) in the presence or not of an 
ntibacterial agent within the composite formulation. Then, bone cell response and antimicrobial activity of the composite have been evaluated in 
itro. Finally, in order to evaluate resorption rate and bone tissue response an animal study has been performed and the histological analysis is still 
n progress. These multidisciplinary and complementary studies led to promising results in a view of the industrial development of such composite 
or dental and orthopaedic applications.
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i. Introduction
As a result of ageing, of various life trauma/accidents and/or
one disease states, the number of bone factures and trauma
ramatically increases especially in the most industrialized
ountries where it raises a public healthcare issue. In this con-
ext, there is an increasing demand in the development of bone
ubstitutes capable of being implanted using minimally invasive
urgical techniques, offering rapid and effective bone repair at
ow cost, limiting postoperative infectious risk and enabling a
∗ Corresponding author.
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nast transfer to industrial scale. In a view to enhance the overall
urgery benefits for the patient, four main characteristics of the
iomaterial have to be considered and investigated: injectabil-
ty, resorbability, biological activity (especially osteogenecity)
nd antibacterial activity. The BIOSINJECT project proposes
olutions to this multiconstraints problem and aims at prepar-
ng a new generation of mineral-organic composites exhibiting
oth bioactivity and therapeutic activity for bone regeneration
t the best cost-efficiency ratio in a view to broaden the appli-
ation domains of the actual bone mineral cements and propose
n alternative strategy with regard to their poor resorbability.
This research program implements an inter- and multidisci-
linary research based on a large consortium gathering eight
ational partners (six academic partners and two industrial
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aig. 1. Schematic representation of the partnership and main tasks establishe
pecialties.
artners [small companies]). It is combining complemen-
ary expertises: material scientists for injectable composite
aterial formulation, chemists to synthesise polymers with
ailor-made properties, rheologists for rheological characterisa-
ion of composite paste, pharmacists for sustained release system
ormulation, microbiologists for antibacterial evaluation of the
omposite, cell biologists for cytocompatibility and biological
ctivity evaluation of the composite in vitro, clinicians for the
nimal study and R&D engineers for production scale-up and
echnology transfer (Fig. 1).
. Mineral and organic components
The matrix of the composite is based on calcium carbonate-
alcium phosphate cements that have been studied and
eveloped at CIRIMAT (Toulouse, France) during the last
ecade [1–3].
In addition, one of the main challenges of this project was
o synthesise tailor-made polymers that can control paste cohe-
iveness and injectability suitable for mini-invasive surgery, drug
elease or biological activity. A patent has been filed on a pro-
ess to prepare new biocompatible polysaccharide derivatives
sing click chemistry [4]. The feasibility of this new method was
emonstrated in the synthesis of hyaluronic acid (HA) deriva-
ives. In addition, functionalisation of a thermosensitive polymer
nd its grafting on HA backbone was also performed. Up to date,
he amounts of chemically modified polymers synthesised using
hese two routes were not enough to fully evaluate the properties
f the mineral-organic composites including these tailor-made
olysaccharides. Consequently, even if these two routes of
c
p
t
sBIOSINJECT project based on each partner’s scientific and/or technological
ynthesis are still in progress, commercial polysaccharide addi-
ives have been chosen for the formulation of the paste used in
his study.
. Composite formulation and physical-chemical
roperties
Different ways of association of the polymer with the self-
etting mineral powder were tested including polymer solution
sed as liquid phase to prepare the composite paste or polymer
articles mixed with the mineral powder before preparing the
omposite paste using water as liquid phase. In the latter case,
he polymer powder was used as received (commercial poly-
er powder) or was previously processed using spray drying
o obtain microspheres with controlled particle size distribu-
ion which could be exploited to control the interconnected
acroporosity of the cement on one hand, and to encapsulate
iologically active agents on the other hand. The introduction of
n antibacterial agent within the composite formulation was also
nvestigated. Several proportions of polysaccharide and antibac-
erial agent were tested.
The injectability of the composite paste placed in a syringe
as evaluated using a protocol previously published [5]. The
etting chemical reaction was followed using complementary
pectroscopic techniques (FTIR spectroscopy and solid state
MR spectrometry). An experimental procedure has been set
nd developed to finely analyse the composite paste rheologi-
al behaviour and the effect of the additives on the viscoelastic
roperties of the composite paste during setting using rheome-
ry. The setting time was determined using the Gillmore needles
tandard method [6].
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•We showed that the introduction of the polysaccharide and
f the antibacterial agent does not prevent the setting reaction
o occur in the tested ranges. In addition the introduction of
polysaccharide improves the injectability of the paste what-
ver the way it is introduced in the paste; it also significantly
ecreased or inhibited the filter pressing phenomenon to occur
uring paste extrusion.
. Composite in vitro and in vivo evaluation
Several biological in vitro studies were performed in the
resence of bacteria or cells in contact with the prepared
omposite to evaluate bone cell and antimicrobial activity.
e evaluated the antibacterial efficiency of the composite
ith/without antimicrobial agent against the main species
nvolved in bone infections e.g. Staphylococcus aureus and
taphylococcus epidermidis using reference strains (Institut Pas-
eur Collection, Paris, France) and clinical isolates. Another
n vitro study was performed using monolayers of human osteo-
rogenitors cells maintained in culture in the presence of the
omposite. The efficiency of the composite with regard to
one cell activity was investigated by measuring cell viabil-
ty (live/dead), proliferation (MTT analysis) and differentiation
etermined by RT-QPCR of osteoprogenitor cells in direct
ontact with the composite. The results of these tests allowed
s to determine the minimal proportion of antibacterial agent
o introduce in the composite formulation in order to be effi-
ient against bacteria and non-cytotoxic with regard to osteoblast
ells.
Finally an animal study was performed to evaluate the refer-
nce mineral cement (without polysaccharide and antibacterial
gent) and the composite material (with polysaccharide and
ntibacterial agent). Cements were implanted in critical size
efects drilled in lateral femoral condyles of rabbits. After
weeks post-implantation, bone neoformation and material
esorption were evaluated using non-decalcified histology and
istomorphometry. For both materials compositions tested, no
oreign body reaction, inflammation or fibrous tissue forma-
ion were observed. The CaCO3-CaP cement showed high
esorption and osteoconductivity. Histological study is currently
n progress for composite specimen and the results will be
ncluded in another paper that will be submitted within the next
onths.
. Communications
Several oral and poster communications where the ANR is
cknowledged have been presented to international and national
onferences:
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O. Marsan, C. Charvillat, C. Rey, C. Combes. Griboi 2011,
Boston (États-Unis), 5–7 April 2011;
C2. Addition of strontium in a calcium carbonate-calcium
phosphate mixed cement: release behaviour and effect on
osteoprogenitor cells (oral). S. Tadier, R. Bareille, R. Siadous,
•S. Cazalbou, O. Marsan, C. Rey, C. Combes. Swiss Con-
ference on Biomaterials (SSB) 2011, Yverdon-les-Bains
(Suisse), 4 May 2011;
C3. Microsphères antibactériennes à base de polysaccha-
rides obtenues par atomisation séchage : incorporation dans
un ciment injectable (oral). M. Fatnassi, S. Girod-Fullana,
C. Cassan, S. Jacquart, C. Rey, C. Combes. Journées de la
société francophone des biomatériaux dentaires (SFBD),
Toulouse, France, 16 and 17 June 2011;
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dentaires (Resorbable and antibacterial cement for den-
tal applications) (oral). S. Jacquart, C. Pigasse, C. Roques,
S. Tadier, C. Rey, C. Combes. Journées de la société franco-
phone des biomatériaux dentaires (SFBD), Toulouse, France,
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S. Jacquart, C. Pigasse, C. Roques, M. Fatnassi, S. Girod-
Fullana, R. Bareille, S. Tadier, C. Rey, C. Combes. Euromat,
September 2011, Montpellier, France;
C6. Controlled release properties of a spray-dried polysac-
charide microspheres – calcium carbonate injectable com-
posite bone cement (oral). M. Fatnassi, S. Girod-Fullana,
S. Jacquart, C. Rey, C. Combes. Euromat, September 2011,
Montpellier, France;
C7. Injectable bone mineral cements: current and future
trends (invited conference). S. Tadier, S. Jacquart, N. Le
Bolay, S. Girod-Fullana, S. Cazalbou, R. Bareille, C. Rey,
C. Combes. Materials Science and Technology 2011. Con-
ference & Exhibition (MS&T’11), Columbus (OH, USA),
16–20 October 2011;
C8. Évaluation des propriétés de relargage d’un ciment
injectable antibactérien : influence de la formulation
(oral). S. Girod-Fullana, S. Jacquart, M. Fatnassi, F. Brouillet,
C. Rey, C. Combes. 2e Rencontre Plateforme Galénique
Avancée, « Amélioration de la biodisponibilité de molécules
bioactives peu solubles dans des milieux aqueux »,
15 December 2011, Castres;
C9. Rheological characterization of calcium carbonate
injectable cements (oral). N. El Kissi, C. Combes, R. Auzely-
Velty. Alpine Rheology Meeting, January 6–13, 2012 – Les
gets, France.
C10. Influence de l’addition de polysaccharide sur
l’injectabilité d’un ciment phosphate-carbonate de cal-
cium. (oral). S. Jacquart, M. Fatnassi, S. Girod-Fullana,
C. Rey, C. Combes. 7e colloque Science et Technolo-
gie des Poudres – STP 2012, 4–6 July 2012, Toulouse,
France;
C11. Élaboration optimisée de microsphères de polysaccha-
rides par atomisation séchage en vue de leur incorporation
dans un ciment minéral injectable (oral). M. Fatnassi,
S. Girod-Fullana, F. Brouillet, S. Jacquart, C. Rey, C. Combes.
7e colloque Science et Technologie des Poudres – STP 2012,
4–6 July 2012, Toulouse, France;
C12. Rheological properties of calcium carbonate self-setting
injectable paste (oral). N. El Kissi, C. Combes, S. Tadier,
S. Girod-Fullana, R. Auzély-Velty. The XVIth International
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[Congress on Rheology, August 5–10, 2012 – Lisbon, Portu-
gal;
C13. Bone tissue response to new calcium carbonate-based
injectable cements (oral). M. Souyet, S. Jacquart, S. Tadier,
H. Petite, C. Rey, C. Combes, F. Anagnostou. The sixth Inter-
national Association for Dental Research Pan-European
Region Meeting, IADR, 12–15 September 2012, Helsinki,
Finland;
C14. Staphylococci biofilm, Control for the development of
an antibacterial composite for bone grafts (poster). C. Pigasse,
C. Roques. Eurobiofilms 2011, 6–8 July 2011, Copenhague
(Denmark);
C15. Designing biomimetic scaffolds based on hyaluronic
acid to stimulate bone repair (poster). A. Belime, R. Siadous,
R. Bareille, J. Amedee, C. Combes, R. Auzely-Velty. ESB
2011, 4–9 September 2011, Dublin, Ireland;
C16. Effects of carrageenan on the injectability of a
mineral bone cement (poster). S. Jacquart, M. Fatnassi,
S. Girod-Fullana, C. Rey, C. Combes. GRIBOI 2012, 22nd
Interdisciplinary Research Conference on Injectable Osteoar-
ticular Biomaterials and Bone Augmentation Procedures,
May 10–12, 2012, Uppsala, Sweden.
. Patent
P1. Dérivés de polysaccharides comportant un motif
aléimide et réaction de couplage par chimie thiol-clic. Auzely
, Belime A, Patent no FR 2967678 (2012).
taff recruited for BIOSINJECT project
Non-permanent staff has been recruited to work full-time on
IOSINJECT project:Jacquart Sylvaine, PhD student (36 months), Institut National
Polytechnique de Toulouse – CIRIMAT, France, (partner 1);
[
[Fatnassi Mohamed, post-doctoral researcher (12 months),
Institut National Polytechnique de Toulouse – CIRIMAT,
France, (partner 1).
Belime Agathe, PhD student (36 months) at Université
Joseph-Fourier, Grenoble – CERMAV, France, (partner 2);
Pigasse Christel, Engineer assistant (18 months), Laboratoire
de Génie Chimique, Toulouse, France, (partner 4);
Siadous Robin, Engineer assistant (9 months), Inserm U1026,
Bordeaux, France, (partner 5);
Post-doctoral researcher (10 months), to be recruited, Labo-
ratoire biomécanique et biomatériaux ostéoarticulaires, Paris,
France, (partner 6).
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